Table 1.
Laboratory data before and after administration of an SGLT2 inhibitor
| Before | After | p | |
|---|---|---|---|
| AST (U/L) | 26±8 | 27±8 | 0.72 |
| ALT (U/L) | 38±21 | 34±20 | 0.012 |
| γGTP (U/L) | 68±54 | 42±26 | 0.013 |
| BUN (mg/dL) | 14.1±5.4 | 16.8±5.2 | 0.046 |
| Cr (mg/dL) | 0.69±0.17 | 0.74±0.18 | 0.16 |
| T.Cho (mg/dL) | 182±34 | 171±34 | 0.039 |
| HDL-C (mg/dL) | 51±17 | 50±17 | 0.37 |
| TG (mg/dL) | 171±87 | 159±97 | 0.57 |
| Ht (%) | 41±6 | 38±15 | 0.54 |
| UA (mg/dL) | 5.5±1.5 | 5.2±1.2 | 0.22 |
| HbA1c (%) | 8.5±1.3 | 7.5±1.0 | 0.0003 |
| BW (kg) | 82.5±20.2 | 80.6±20.9 | 0.013 |
Before and after administration of SGLT2 inhibitors.
ALT, alanine transaminase; AST, aspartate transaminase; BW, body weight; BUN, blood urea nitrogen/creatinine; γGTP, γ-glutamyltranspeptidase; Cr, creatinine; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein - cholesterol; Ht, hematocrit; SGLT2, sodium-glucose co-transporter 2; T.Cho, total cholesterol; TG, triglyceride; UA, uric acid.